Introduction
Classical pharmacological approaches and, more recently, studies in gene knockout mice have shown that stimulation of dopamine D 1 -like (D 1 and D 5 ) and D 2 -like (D 2L/S , D 3 and D 4 ) receptors can lower and elevate seizure threshold, respectively (Starr, 1996; Weinshenker and Szot, 2002) . Interestingly, the ability of selective D 1 -like agonists to induce seizures (DeNinno et al., 1991; Holmes et al., 2001) appears to be critically dependent on their intracellular signal transduction coupling. Specifically, the selective D 1 -like agonist SKF 83822, which stimulates adenylate cyclase (AC), but not phospholipase C (PLC)-mediated phosphoinositide hydrolysis (Undie et al., 1994; Peacock and Gerlach, 2001; Rashid et al., 2007) , induces prominent behavioral seizures in mice (O'Sullivan et al., 2004) , whereas its benzazepine congener SKF 83959, which stimulates PLC, but not AC (Panchalingam and Undie, 2001; Jin et al., 2003; Rashid et al., 2007) , does not. Furthermore, induction of behavioral seizures following challenge with SKF 83822 is conserved in congenic D 5 knockout mice, indicating that among D 1 -like receptors, selective D 1 receptor coupling to AC may be important in seizure susceptibility .
In recent years, it has become apparent that downstream signalling at AC-linked D 1 -like receptors is more complex than previously envisaged. Dopamine and cAMP-regulated phosphoprotein, Mw 32kDa (DARPP-32) is a signal integration molecule that functions as a potent inhibitor of protein phosphatase 1 (PP1) when phosphorylated at Thr34 by protein kinase A (PKA) and an inhibitor of PKA when phosphorylated at Thr75 by cyclin-dependent kinase 5 (Svenningsson et al., 2004) . In addition, it has now been established that DARPP-32-mediated inhibition of PP1 can also activate extracellular-regulated kinases 1 and 2 (ERK1/2; Valjent et al., 2000 Valjent et al., , 2005 Girault et al., 2007) . ERK1/2 are members of the mitogen activated protein kinase (MAPK) family and are known to be involved in diverse biological processes, 5 including synaptic plasticity and epileptogenesis (Merlo et al., 2004; Thomas and Huganir, 2004) . Evidence for D 1 -like receptor linkage to MAPK signalling has recently emerged with the finding that dopamine-induced cytotoxicity involves D 1 receptor-mediated ERK1/2 activation (Chen et al., 2004) .
A functional role for dopamine in seizure generation has traditionally received little attention, with the majority of research focused on glutamatergic and GABAergic mechanisms. However, recent findings that (a) phosphorylation of the AMPA receptor subunit GluR1 at Serine 845 is increased in response to DARPP-32-mediated inhibition of PP1 (Snyder et al., 2000) and (b) AMPA receptor cell surface expression is up-regulated following D 1 receptor activation in a PKA-dependent manner (Mangiavacchi and Wolf, 2004) demonstrate that dopamine can potentiate excitatory glutamatergic transmission. Finally, immunoblotting has been employed to identify possible roles for ERK1/2 activation and functional dopamine-glutamate interactions in these processes.
Materials and methods

Mutant mice
For behavioral and EEG studies, the original F2 hybrid (129 × C57BL/6) strain containing the mutated D 1 receptor, D 5 receptor and DARPP-32 alleles were generated as 6 reported previously (Drago et al., 1994; Fienberg et al., 1998; Hollon et al., 2002) . To establish congenic lines, heterozygous knockouts of these hybrid D 1 , D 5 and DARPP-32 strains were backcrossed to wild-type C57BL/6 for 15, 10 and 11 generations, respectively (McNamara et al., 2003; Nally et al., 2004; O'Sullivan et al., 2005) . Analysis of isolated genomic DNA by PCR was used to genotype the progeny of heterozygous D 1 , heterozygous D 5 and homozygous DARPP-32 intermatings. For each knockout line, wild-type, heterozygous and homozygous knockout littermates of the same generational age from these intermatings were used. For biochemical studies, adult male C57BL/6 mice (Charles River, Sulzfeld, Germany) weighing 25 -30 g were used. Mice were housed in groups of five, with standard laboratory chow and water available ad libitum, and were maintained at 21 ± 1°C on a 12 h/12 h (08:00 on; 20:00 off) light/dark schedule. All efforts were made to minimize the number of animals used and their suffering. 
Behavioral assessment
For evaluation of the SKF 83822-induced ethogram, female homozygous D 1 knockout and wild-type mice were removed from their home cage and placed individually in clear glass observation cages (36 × 20 × 20 cm) with wood shavings as bedding material. Mice were then allowed to habituate for a period of 3 h to reduce initially high levels of activity in order to optimise detection of agonist-induced stimulatory effects. Immediately following challenge with SKF 83822 (0.016 -2.0 mg/kg s.c.) or vehicle, assessments were carried out using a 7 rapid time-sampling behavioral checklist technique and stereotypy rating scale, as previously described (Nally et al., 2004; c, 2006; O'Tuathaigh et al., 2006) . For this study, the following components of the ethogram are reported: sniffing (flaring of nostrils with movement of vibrissae); locomotion (coordinated movement of all four limbs producing a change in location); rearing to wall (front paws reaching upwards onto or towards a cage wall while standing on hind limbs); total grooming (grooming of any form); intense grooming (characteristic, programmed syntax of sequential grooming of the snout and then the face with the forepaws, followed by grooming of the hind flank/anogenital region with the snout); seizures, characterised as any of the following phases occurring within the 60 min observation period: phase 1 = sustained immobility/rigidity; phase 2 = rearing with forepaw myoclonus; phase 3 = generalized clonus; phase 4 = tonic-clonic seizure or rapid jumping and wild running (Ferraro et al., 1999; McKhann et al., 2003; O'Sullivan et al., 2006) ; stillness (motionless: awake with no behavior evident, or asleep). Under these conditions mice were used on two occasions only, separated by a drug-free interval of at least one week; on each occasion mice were allocated randomly to one of the various treatment groups. All assessments were made by an observer who was unaware of genotype and treatment for each animal.
Electroencephalographic recording
Seizure studies were carried out in a manner similar to that described previously (Shinoda et al., 2004) . Briefly, for surgical implantation of extradural recording electrodes, adult male D 1 , D 5 or DARPP-32 knockouts or wild-types were initially anaesthetised using 5% isoflurane (Abbott Laboratories, Kent, UK) in O 2 , placed in a stereotaxic frame and maintained under anaesthesia using 1.5% isoflurane in O 2 . Temperature was maintained 8 normothermic (37 ± 0.5°C) by means of a rectal thermometer and thermostatically controlled heating pad (Harvard Apparatus, MA, USA). The scalp was incised and a burr hole drilled in the exposed cranium over each hippocampus and the frontal cortex. Bitemporal recording electrodes and a frontal reference electrode (Plastics One Inc., VA, USA) were then affixed to the skull using dental cement (Kemdent, Wiltshire, UK). Following surgery, animals were placed in an incubator (Harvard Apparatus, MA, USA) to recover from anaesthesia before being returned to their homecage. 24 -48 h post-surgery, experimental animals were connected to a digital EEG monitoring apparatus (AS40 amplifier system; Grass Technologies, RI, USA) and a 30 min baseline EEG was recorded before administration of SKF 83822 (2.0 mg/kg s.c.) or vehicle. EEGs were recorded for 1 h post-injection and subsequently analysed by a trained observer unaware of genotype or treatment for each animal; to ensure delayed seizure events were not present, a 5 h EEG was recorded following administration of SKF 83822 for each mutant line on at least one occasion. EEG patterns were classified as previously described (Shinoda et al., 2004) : type I = baseline recording; type II = high frequency (> 1 Hz), low voltage spiking (no behavioral correlate); type III = low frequency (< 1 Hz), high voltage spiking (corresponding to a phase 2/3 behavioral seizure above); type IV = high frequency, high voltage spiking (corresponding to a phase 4 behavioral seizure above).
Tissue extraction procedures
For phosphoprotein determination in whole brain structures, male C57BL/6 mice were sacrificed by decapitation at specific time points (15, 30 or 60 min) following challenge with SKF 83822 (2.0 mg/kg s.c.) or vehicle and heads immediately immersed in liquid nitrogen for 6 s. The brains were then removed, and the striatum and hippocampus rapidly dissected on an 9 ice-cold surface, sonicated in 1% sodium dodecyl sulfate and boiled for 10 min. This procedure prevents protein phosphorylation and dephosphorylation which occur very rapidly post-mortem (Svenningsson et al., 2000) . For preparation and incubation of striatal slices, male C57BL/6 mice were decapitated and the brains rapidly dissected out on an ice-cold surface and cut in 250 µm coronal slices using a Leica VT1000S vibrating blade microtome (Leica Microsystems AB, Kista, Sweden). Dorsal striata were dissected out from each slice under a microscope. Two striatal coronal slices were randomly placed in individual 5 ml polypropylene tubes containing 2 ml of Krebs-Ringer biocarbonate buffer (KRB in mM: NaCl 118, KCl 4.7, CaCl 2 1.3, MgSO 4 1.5, KH 2 PO 4 1.2, NaHCO 3 25 and glucose 11.7; equilibrated with 95% O 2 , 5% CO 2 [v/v] , pH 7.3). The samples were incubated at 30°C for two 30 min periods, each followed by replacement with 2 ml fresh KRB buffer. Samples were then incubated with either SKF 83822 (1µM) or vehicle for 5 min. The reaction was rapidly terminated by removing the medium, sonicating the slices in 1% sodium dodecyl sulfate and boiling for 10 min.
Determination of phosphoproteins
Determination of protein phosphorylation was carried out in a manner similar to that described previously (Hakansson et al., 2006) . Briefly, aliquots (5 µl) of the homogenate were used for protein determination using the bicinchoninic acid method (Pierce, Oud Beijerland, Netherlands). Equal amounts of protein (30 µg) from each sample were loaded onto 10% polyacrylamide gels. Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to either Immobilon-FL transfer membranes (Millipore, MA, USA) or polyvinylidine diflouride membranes (Amersham Pharmacia Biotech, Uppsala, Sweden), as previously described (Towbin et al., 1979) . Membranes were then immunoblotted using affinity-purified polyclonal antibodies that selectively detect phosphoSer845-GluR1 (Upstate, NY, USA) or phospho-Thr183/Tyr185-ERK1/2 (Cell Signalling Technology, MA, USA), or a monoclonal antibody against phospho-Thr34-DARPP-32 (Snyder et al., 1992) . Antibodies against GluR1 (Upstate, NY, USA), ERK1/2 (Cell Signalling Technology, MA, USA) and DARPP-32 (Hemmmings and Greengard, 1986 ) that are not phosphorylation state-specific were used to estimate the total amount of proteins.
Antibody binding was revealed by either one of the following two techniques. In experiments where the ECL immunoblotting detection method was employed, a goat anti-mouse horseradish peroxidase-linked IgG (Pierce, Oud Beijerland, Netherlands) was used as a secondary antibody and the resulting chemiluminescent signal was detected by autoradiography. Quantification of the bands corresponding to the phosphorylated or nonphosphorylated proteins was by densitometry using NIH Image software (version 1.63).
Alternatively, detection was performed using fluorescent secondary antibodies (Molecular probes, OR, USA and Rockland Immunochemicals, PA, USA). On these occasions, quantification of antibody binding was by fluorimetry using a Li-Cor Odyssey infrared fluorescent detection system (Li-Cor, NE, USA).
Drugs
The following drugs were used: SKF 83822 [6-chloro-2,3,4,5-tetrahydro-1-(3-methylphenyl)-3-(2-propenyl)-1H-3-benzazepine-7,8-diol hydrobromide; Tocris Bioscience, Bristol, UK]; SKF 83959 [3-methyl-6-chloro-7,8-dihydroxy-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; RBI/SRI/NIMH Chemical Synthesis Program, USA]. SKF 83822 was dissolved in 0.5% dimethyl sulfoxide and administered subcutaneously into the flank in a volume of 4.0 ml/kg; control mice received 0.5% dimethyl sulfoxide alone administered in an identical manner. SKF 83959 was dissolved in distilled water and administered subcutaneously into the flank in a volume of 2.0 ml/kg; control mice received distilled water alone in an identical manner.
Data analysis
As described previously (Nally et al., 2004; O'Sullivan et al., 2004 O'Sullivan et al., , 2006 O'Tuathaigh et al., 2006) , for specification of the agonist-induced ethogram, the total 'counts' for each individual behavior were determined as the number of 5 s observation windows in which a given behavior was evident, summed over the 3 × 15 min [0 -15, 20 -35, 40 -55] cycle periods; data were expressed as means ± SEM. Stereotypy scores were averaged over the 60 min period and expressed similarly. 'Counts' for individual behaviors in relation to agonist dose were analysed using ANOVA after square-root transformation followed by Student's ttest; stereotypy scores were analysed using the Kruskal-Wallis nonparametric ANOVA followed by Mann-Whitney U-test. For determination of protein phosphorylation in whole striatum/hippocampus and striatal slices, densitometry values were analysed using ANOVA followed by Dunnett's test and Student's t-test, respectively.
Results
Ethological response to SKF 83822 in D 1 knockouts
On examining 11 female homozygous congenic D 1 knockout mice, mean body weight (19±1 g, mean age 184±11 days) was reduced (-20%, p < 0.001) relative to 15 female wildtype controls (23±1 g, mean age 187±8 days (Fig. 2, Table 1 ).
In both heterozygous and homozygous D 5 knockouts, latency to first seizure was significantly increased (+59%, p < 0.01), with significant reductions in the overall number of seizures (-75%, p < 0.01) and type IV events (-87%, p < 0.05) in homozygous D 5 knockouts relative to wild-types. The majority (60%) of homozygous DARPP-32 knockouts did not have seizures;
of those evidencing seizures (40%), latency to first seizure was significantly increased (+61%, p < 0.01), while the overall number of seizures and type IV events were reduced (-80%, p < 0.05 and -75%, p < 0.05 respectively) relative to wild-types.
SKF 83822-and SKF 83959-induced protein phosphorylation in the striatum and hippocampus
At 15 min post administration of SKF 83822 (2.0 mg/kg s.c.), levels of ERK1/2 phosphorylation increased 2.5-fold in both the striatum [ERK1, F(3,42) = 7.2, p < 0.001; ERK2, F(3,42) = 6.1, p < 0.01] and hippocampus [ERK1, F(3,41) = 8.9, p < 0.001; ERK2, F(3,41) = 9.1, p < 0.001] and remained significantly elevated throughout the 60 min assessment period (Fig. 3a,b) . In contrast, systemic administration of PLC-stimulating SKF 83959 (2.0 mg/kg) had no effect on ERK1/2 phosphorylation in the striatum (Fig. 3c); however, a minor but significant increase in ERK1/2 phosphorylation following challenge with SKF 83959 was detected in the hippocampus at 15 and 60 min [ERK1, F(3,21) = 5.6, p < 0.01; ERK2, F(3,21) = 4.2, p < 0.05] (Fig. 3d) . SKF 83822 also induced prominent GluR1
AMPA receptor phosphorylation at Ser845 in both the striatum [F(3,42) = 32.3, p < 0.001] and hippocampus [F(3,42) = 27.7, p < 0.001] after 15 min and this effect was maintained at 14 subsequent time points (Fig. 4a,b) . In contrast, PLC-stimulating SKF 83959 induced only modest Ser845 GluR1 phosphorylation in the striatum at later time points [F(3,21) = 4.6, p < 0.05] and was without effect on basal levels of Ser845 GluR1 phosphorylation in the hippocampus (Fig 4C, D) . Phosphorylation of DARPP-32 at Thr34 in response to SKF 83822 was more complex: the scatter plot in Fig. 5b shows up to a two-fold increase in some animals yet up to a two-fold decrease in others, resulting in no overall effect of SKF 83822 on mean DARPP-32 phosphorylation in the striatum at any time point (Fig. 5a) ; rather, variance in SKF 83822-induced DARPP-32 phosphorylation markedly exceeded that in vehicle-treated controls at 15, 30 and 60 min [F(10,11) = 9.9, F(11,11) = 10.1 and F(11,11) = 8.9, respectively, each p < 0.001]. However, in striatal slices, a five-fold increase in DARPP-32 phosphorylation at Thr34 was recorded 5 min post-SKF 83822 administration relative to vehicle-treated controls (p < 0.001) (Fig. 5c) . In contrast, administration of PLC-stimulating SKF 83959 reduced levels of DARPP-32 phosphorylation at Thr34 in the striatum at intermediate time points [F(3,21) = 3.3, p < 0.05] relative to vehicle-treated controls (Fig. 5a ).
Due to very low basal levels of DARPP-32 expression in the hippocampus, phosphorylation of this protein in response to SKF 83822 and SKF 83959 was not examined.
Discussion
Determining the precise functional roles of individual dopamine D 1 -like receptors has been complicated at two levels. (Clifford et al., 1999; McNamara et al., 2003; O'Sullivan et al., 2005 O'Sullivan et al., , 2006 , provides strong evidence that the ability of certain D 1 -like agonists to lower seizure threshold (DeNinno et al., 1991; Starr and Starr, 1993 It is well established that DARPP-32 is an important integrator of signal transduction pathways involving cAMP-dependent activation of PKA in dopaminoceptive neurons (Svenningsson et al., 2004 where it is a full agonist at the D 1 receptor and a partial agonist at the D 2 receptor; D 2 receptor activation inhibits DARPP-32 phosphorylation at Thr34 and is known to be anticonvulsant (Bozzi et al., 2000; Svenningsson et al., 2004 Svenningsson et al., , 2005 .
In this study, we show that the AC-stimulating agonist SKF 83822, but not the PLCstimulating agonist SKF 83959, induces prominent ERK1/2 phosphorylation in both the hippocampus and striatum, suggesting that seizure induction at D 1 -like receptors involves AC-dependent activation of ERK1/2 signalling. ERK1/2 are implicated in the modulation of dendritic potassium channels in the hippocampus (Watanabe et al., 2002; Yuan et al., 2002) .
In particular, ERK-dependent phosphorylation of the Kv4.2 potassium channel subunit has been shown to reduce A-type currents and increase excitability of CA1 pyramidal neurons, an effect that could be involved in epileptiform activity (Francis et al., 1997) . It has recently been reported that ERK signalling at D 1 receptors occurs via an AC/PKA/DARPP-32 pathway, as the ability of amphetamine to induce ERK activation is absent in DARPP-32 mutants (Valjent et al., 2005) . It is unclear if a similar mechanism is responsible for ERK1/2 activation in the present study; however, the fact that SKF 83822-induced seizures were observed in a small number of DARPP-32 knockouts suggests that additional signalling pathways exist which permit ERK1/2 activation in response to seizure-producing stimulation of D 1 -like receptors.
In this regard, D 1 receptor stimulation has been shown to facilitate glutamatergic synaptic transmission through the modulation of N-methyl-D-aspartate and AMPA receptor function (Levine et al., 1996; Cepeda et al., 1998; Snyder et al., 2000; Mangiavacchi and Wolf, 2004) which can, in turn, activate ERK1/2 in a DARPP-32-independent manner (Valjent et al., 2005; Girault et al., 2007) . Our finding that SKF 83822, but not SKF 83959, induces prominent phosphorylation of the AMPA receptor subunit GluR1 at Serine 845 suggests that similar processes might be responsible, at least in part, for the increase in ERK1/2 phosphorylation observed here. Given that ERK1/2 activation has recently been observed in response to seizure-producing stimuli at non-dopamine receptors (Merlo et al., 2004) , it is 20 plausible that ERK1/2 function as coincident detectors of generalised epileptiform activity.
Although targeted deletion of the ERK2 gene is lethal in utero (Yao et al., 2003; Saba-El-Leil et al., 2003) , future studies examining the seizure profile of diverse chemoconvulsants, including SKF 83822, in ERK1 knockouts (Pages et al., 1999) or in combination with SL327
(an upstream inhibitor of ERK) may reveal novel strategies for seizure prevention. Given the present effects of SKF 83822 on the phosphorylation of DARPP-32, ERK1/2 and GluR1-AMPA receptor subunits in wild-type mice, a priority for future experiments will be to test the hypothesis that phosphorylation of these proteins is reduced in D 1 /D 5 receptor and DARPP-32 knockouts receiving a convulsant dose of SKF 83822. Additionally, characterising the effects of SKF 83822 in other brain regions related to seizures such as the cerebral cortex and on the phosphorylation and expression of individual GABA receptor subtypes will be important in elucidating further the precise dopaminergic mechanisms involved in seizure generation.
In conclusion, the present findings, together with previous studies in our laboratory (McNamara et al., 2003; O'Sullivan et al., 2005) , confirm that discrete elements of D 1 receptor function involve exclusive coupling to AC, while others are mediated by coupling to PLC. We have shown that the ability of D 1 -like receptor stimulation to lower seizure threshold involves DARPP-32 and perhaps ERK1/2 activation, possibly via functional interaction with glutamatergic signalling. Given well-described species differences in response to centrally acting dopamine agonists, the clinical implications of the pre-clinical findings reported here remain to be clarified. Regardless, considering the need for improved therapeutic strategies in epilepsy, further research evaluating the role of D 1 receptor signalling in seizure processes is warranted. 
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